An Experimental Study of Regional Chemotherapy Using CDDP-Loaded Microspheres for Esophageal Cancer

Abstract

These results demonstrate that a high dose of CDDP can be administered with less systemic side effects by means of encapsulation in the microspheres, and that the administration of CDDP-MS into the mediastinum is more effective for delivering CDDP to the paratracheal lymph nodes. As a regional chemotherapy after esophageal cancer operation, the injection of CDDP-MS into the mediastinum for targeting of the lymph nodes thus promises to be an effective treatment.

Biodegradable microparticles and fiber fabrics for sustained delivery of cisplatin to treat C6 glioma in vitro

“…Despite its success, cisplatin has several drawbacks including many side effects (e.g., nephrotoxicity, neurotoxicity, and emetogensis) and limited solubility in aqueous solution (typical dose 100 mg/day for up to 5 consecutive days) 2. Therefore, various drug delivery devices including lipsomes,5, 6 micelles,7–9 nanoparticles,10 carbon nanohorns,11, 12 microparticles,13–19 and composite microparticles (PLA/PLGA)20, 21 have been developed to minimize the side effects and to improve the efficacy of its therapy. In addition, Burger et al and Ramachandran et al reported cisplatin nanolipsomes and lipid‐coated aggregates of cisplatin, respectively.…”

Activated carbon nanoparticles or methylene blue as tracer during video‐assisted thoracic surgery for lung cancer can help pathologist find the detected lymph nodes

“…The colloidal particles administered interstitially are mainly taken up by the regional lymphatic system and accumulate to varying degrees in the lymph nodes in our previous study [14]. This unique selective biodistribution led to the development of lymphatic targeting drug delivery systems utilizing colloidal materials as drug carriers, such as liposomes [15], activated carbon particles [16], emulsions [17], lipids [18], and various polymeric particulates [19].…”

Targeting colloidal particulates to thoracic lymph nodes

“…A consistent finding in these studies is that the colloidal particles administered interstitially are mainly taken up by the regional lymphatic system and accumulate to varying degrees in the lymph nodes. This unique selective biodistribution led to the development of lymphatic targeting drug delivery systems utilizing colloidal materials as drug carriers, such as liposomes [8][9][10], activated carbon particles [11,12], emulsions [13,14], lipids [15] and various polymeric particulates [16,17]. However, lymphatic distribution of particles of different materials and sizes following intrapleural administration has not been investigated.…”